financetom
Business
financetom
/
Business
/
Cheniere Energy Partners Maintains Quarterly Distribution
News World Market Environment Technology Personal Finance Politics Retail Business Economy Cryptocurrency Forex Stocks Market Commodities
Cheniere Energy Partners Maintains Quarterly Distribution
Oct 27, 2024 1:59 AM

10:17 AM EDT, 10/25/2024 (MT Newswires) -- Cheniere Energy Partners ( CQP ) said Friday it set a quarterly cash distribution of $0.810 per unit, payable Nov. 14 to unitholders of record as of Nov. 4.

This distribution consists of a base amount of $0.775 and a variable amount of $0.035, the company said.

Shares of Cheniere Energy Partners ( CQP ) were up 1% in recent trading.

Price: 48.96, Change: +0.49, Percent Change: +1.01

Comments
Welcome to financetom comments! Please keep conversations courteous and on-topic. To fosterproductive and respectful conversations, you may see comments from our Community Managers.
Sign up to post
Sort by
Show More Comments
Related Articles >
Core & Main's Fiscal Q3 Earnings, Net Sales Rise; Fiscal 2024 Sales Guidance Lifted
Core & Main's Fiscal Q3 Earnings, Net Sales Rise; Fiscal 2024 Sales Guidance Lifted
Dec 3, 2024
07:45 AM EST, 12/03/2024 (MT Newswires) -- Core & Main ( CNM ) reported fiscal Q3 earnings Tuesday of $0.69 per share, up from $0.65 a year earlier. Four analysts polled by FactSet expected $0.64. Net sales for the quarter ended Oct. 27 were $2.04 billion, up from $1.83 billion a year earlier. Analysts surveyed by FactSet expected $1.99 billion....
Gilead Sciences Partners With Tubulis on Antibody-Drug Conjugate Development for Solid Tumors
Gilead Sciences Partners With Tubulis on Antibody-Drug Conjugate Development for Solid Tumors
Dec 3, 2024
07:45 AM EST, 12/03/2024 (MT Newswires) -- Gilead Sciences ( GILD ) said Tuesday it has entered into an exclusive option and license agreement with Tubulis to discover and develop an antibody-drug conjugate, or ADC against a solid tumor target. Gilead will receive access to Tubulis' Tubutecan and Alco5 platforms to design a Topoisomerase I inhibitor-based ADC, the company said....
BRIEF-Accord Biopharma Announces Agreement By Intas Pharmaceuticals, Ltd. To Acquire Udenyca® (Pegfilgrastim-Cbqv) Business From Coherus Biosciences, Inc., Unlocking Potential For Continued U.S. Growt
BRIEF-Accord Biopharma Announces Agreement By Intas Pharmaceuticals, Ltd. To Acquire Udenyca® (Pegfilgrastim-Cbqv) Business From Coherus Biosciences, Inc., Unlocking Potential For Continued U.S. Growt
Dec 3, 2024
Dec 3 (Reuters) - * ACCORD BIOPHARMA ANNOUNCES AGREEMENT BY INTAS PHARMACEUTICALS, LTD. TO ACQUIRE UDENYCA® (PEGFILGRASTIM-CBQV) BUSINESS FROM COHERUS BIOSCIENCES, INC., UNLOCKING POTENTIAL FOR CONTINUED U.S. GROWTH Source text: ...
Enbridge Provides 2025 Guidance; Raises Dividend by 3%
Enbridge Provides 2025 Guidance; Raises Dividend by 3%
Dec 3, 2024
07:42 AM EST, 12/03/2024 (MT Newswires) -- Enbridge ( ENB ) said Tuesday that it expects full-year 2025 adjusted earnings per share to be in a range of CA$5.50 to CA$5.90 ($3.92 to $4.20). Analysts polled by Factset expect $3.01 Enbridge ( ENB ) also said it raised its quarterly dividend by 3% to $0.9425 from $0.915 per share. The...
Copyright 2023-2026 - www.financetom.com All Rights Reserved